Sinopharm Biological (09688): Updates on the Phase 1b/3 clinical study FORTITUDE-102 of Amgen's Bevacizumab Biosimilar

Wisdom Financial News App News, Reignwood Pharmaceuticals (09688) has announced that during their third quarter financial report announcement on November 4, 2025, their partner and research sponsor, Anjin Company, announced the discontinuation of the phase 1b/3 clinical study FORTITUDE-102 evaluating the combination of Pembrolizumab with chemotherapy and Nivolumab for first-line gastric cancer due to insufficient efficacy as indicated by an interim analysis requested by the Data Monitoring Committee.